RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Icagen, Inc. (NASDAQ: ICGN) announced today the expansion of its drug discovery and development expert panel with the appointment of three distinguished academicians. The purpose of Icagen’s drug discovery and development expert panel is to provide ongoing advice and guidance on key scientific and clinical development issues related to the Company’s portfolio of drug discovery programs. The academic members joining this panel are William Catterall, Ph.D., Christine Sang, M.D., M.P.H. and Cheryl Zimmerman, Ph.D.
